NT-ProBNP predicts rhythm stability after cardioversion of lone atrial fibrillation

Circulation Journal

Volumn 72, Issue 6, 2008, Pages 921-925

  Möllmann, Helge ^a   Weber, Michael ^a   Elsässer, Albrecht ^a   Nef, Holger ^a   Dill, Thorsten ^a   Rixe, Johannes ^a   Schmitt, Jörn ^b   Sperzel, Johannes ^a   Hamm, Christian W ^a  

^a KERCKHOFF HEART CENTER   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Atrial fibrillation; Cardioversion; NT proBNP; Rhythm stability

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CARDIOVERSION; DIRECT CURRENT; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART RHYTHM; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; RELAPSE; SINUS RHYTHM;

AGED; AREA UNDER CURVE; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; RECURRENCE;

EID: 45849129753     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.921     Document Type: Article

References (31)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
2. Furberg CD, Psaty BM, Manoho TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-241.
3. Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, et al. Characterization of different subsets of atrial fibrillation in general practice in France: The ALFA study: The College of French Cardiologists. Circulation 1999; 99: 3028-3035.
4. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
5. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-364.
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988.
7. McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: Review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139: 1018-1033.
8. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: S429-S456.
9. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen K-V et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48: 854-906.
10. Nattel S, Opie LH. Controversies in atrial fibrillation. Lancet 2006; 367: 262-272.
11. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
12. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
13. Shin DI, Jaekel K, Schley P, Sause A, Muller M, Fueth R, et al. Plasma levels of NT-pro-BNP in patients with atrial fibrillation before and after electrical cardioversion. Z Kardiol 2005; 94: 795-800.
14. Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H. Brain natriuretic peptide predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm. Can J Cardiol 2004; 20: 1245-1248.
15. Kurosaki K, Tada H, Hashimoto T, Ito S, Miyaji K, Naito S, et al. Plasma natriuretic peptide concentrations as a predictor for successful catheter ablation in patients with drug-refractory atrial fibrillation. Circ J 2007; 71: 313-320.
16. Wozakowska-Kaplon B, Opolski G. Concomitant recovery of atrial mechanical and endocrine function after cardioversion in patients with persistent atrial fibrillation. J Am Coll Cardiol 2003; 41: 1716-1720.
17. Ohta Y, Shimada T, Yoshitomi H, Inoue S, Murakami Y, Shimizu H, et al. Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Can J Cardiol 2001; 17: 415-420.
18. Wozakowska-Kaplon B, Opolski G. Effects of sinus rhythm restoration in patients with persistent atrial fibrillation: A clinical, echocardiography and hormonal study. Int J Cardiol 2004; 96: 171-176.
19. Lee SH, Jung JH, Choi SH, Lee N, Park WJ, Oh DJ, et al. Determinants of brain natriuretic peptide levels in patients with lone atrial fibrillation. Circ J 2006; 70: 100-104.
20. Weber M, Kleine C, Keil E, Rau M, Berkowitsch A, Elsaesser A, et al. Release pattern of N-terminal pro B-type natriuretic peptide (NT-proBNP) in acute coronary syndromes. Clin Res Cardiol 2006; 95: 270-280.
21. Sakai H, Tsutamoto T, Ishikawa C, Tanaka T, Fujii M, Yamamoto T, et al. Direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP secretion and extent of coronary artery stenosis in patients with stable coronary artery disease. Circ J 2007; 71: 499-505.
22. Ogawa A, Seino Y, Yamashita T, Ogata K, Takano T. Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome. Circ J 2006; 70: 1372-1378.
23. Weber M, Hausen M, Arnold R, Nef H, Möllmann H, Berkowitsch A, et al. Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis. Heart 2006; 92: 1639-1644.
24. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006; 52: 1528-1538.
25. Buob A, Jung J, Siaplaouras S, Neuberger HR, Mewis C. Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol 2006; 29: 559-563.
26. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000; 6: 92-96.
27. Goetze JP, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH. Atrial secretion of B-type natriuretic peptide. Eur Heart J 2006; 27: 1648-1650.
28. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26: 2083-2092.
29. Camm AJ, Evans KE, Ward DE, Martin A. The rhythm of the heart in active elderly subjects. Am Heart J 1980; 99: 598-603.
30. Kerr C, Boone I, Connolly S, Greene M, Klein G, Sheldon R, et al. Follow-up of atrial fibrillation: The initial experience of the Canadian Registry of Atrial Fibrillation. Eur Heart J 1996; 17(Suppl C): 48-51.
31. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: A 30-year follow-up study. Circulation 2007; 115: 3050-3056.